Publications by authors named "Marilia Andreia Fernandes"
Article Synopsis
- * In a study of 178,640 patients, those without respiratory symptoms were generally older (median age 74) and had a lower ICU admission rate (36.7%) compared to those with symptoms (37.5%).
- * Despite a higher crude in-hospital death rate for NRS patients (41.1% vs. 32.0%), after adjusting for other factors, they had a lower overall risk of death (HR 0.88), highlighting the complexity of COVID-19 presentations and outcomes.
Pericarditis is a common condition with numerous aetiologies. Bacteria other than the complex are an exceptional cause. We present a case of subacute pericarditis highly probable due to subsp.
View Article and Find Full Text PDFInappropriate polypharmacy is highly prevalent among older adults and presents a significant healthcare concern. Conducting medication reviews and implementing deprescribing strategies in multimorbid older adults with polypharmacy are an inherently complex and challenging task. Recognizing this, the Special Interest Group on Pharmacology of the European Geriatric Medicine Society has compiled evidence on medication review and deprescribing in older adults and has formulated recommendations to enhance appropriate prescribing practices.
View Article and Find Full Text PDFPurpose: To provide an overview of the current deprescribing attitudes, practices, and approaches of geriatricians and geriatricians-in-training across Europe.
Methods: An online survey was disseminated among European geriatricians and geriatricians-in-training. The survey comprised Likert scale and multiple-choice questions on deprescribing approaches and practices, deprescribing education and knowledge, and facilitators/barriers of deprescribing.
A Systematic Review of the Current Evidence from Randomised Controlled Trials on the Impact of Medication Optimisation or Pharmacological Interventions on Quantitative Measures of Cognitive Function in Geriatric Patients.
Drugs Aging
November 2022
Background: Cognitive decline is common in older people. Numerous studies point to the detrimental impact of polypharmacy and inappropriate medication on older people's cognitive function. Here we aim to systematically review evidence on the impact of medication optimisation and drug interventions on cognitive function in older adults.
View Article and Find Full Text PDFCorrection to: Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials.
Eur J Clin Pharmacol
October 2021
Purpose: In the pathogenesis of severe COVID-19 complications, derangements of renin-angiotensin-aldosterone system (RAAS), vascular endothelial dysfunction leading to inflammation and coagulopathy, and arrhythmias play an important role. Therefore, it is worth considering the use of currently available drugs to protect COVID-19 patients with cardiovascular diseases.
Methods: We review the current experience of conventional cardiovascular drugs [angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, anticoagulants, acetosalicylic acid, antiarrhythmic drugs, statins] as well as some other drug classes (antidiabetic drugs, vitamin D and NSAIDs) frequently used by older patients with cardiovascular diseases.
Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials.
Eur J Clin Pharmacol
January 2021
Article Synopsis
- - The relationship between polypharmacy and frailty in older adults suggests a connection, but no causal link has been proven specifically for those already experiencing frailty.
- - A review of studies published between 1998 and 2019 identified 25 randomized controlled trials focusing on how medications affect frailty, with some showing positive outcomes from specific drug interventions on aspects like physical performance and muscle strength.
- - Overall, findings remain inconclusive regarding the impact of drugs on frailty, highlighting the need for further, well-structured trials that consistently assess frailty across different studies.